Marshall Urist sold $786K of Royalty Pharma (RPRX)

Executed Dec 26 2025, disclosed Dec 29 2025, 3 days later.

Value, as filed

$786K

20,000 sh × $39.32

Executed

Dec 26 2025

the trade date, as filed

Disclosed

Dec 29 2025

3 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Marshall Urist EVP, Research & Investments profile →

Marshall Urist (EVP, Research & Investments) filed 14 Form 4 reports in the trailing twelve months (0 purchases, 14 sales), most often in Royalty Pharma plc (RPRX). The largest single filing was $1.7M of RPRX (41,575 sh across 2 lots, as filed), executed Dec 1 2025.

The name

RPRX

Royalty Pharma plc RPRX · Healthcare · 36 filings in 24 months ticker →

Healthcare · Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the U…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Marshall Urist in RPRX

RPRXSALE Royalty Pharma plc $508K
9,099 sh × $55.88
Exec Jul 1
Filed Jul 2 · 4:10 PM ET RPRXSALE Royalty Pharma plc $502K
9,098 sh × $55.18
Exec Jun 24
Filed Jun 25 · 5:30 PM ET RPRXSALE Royalty Pharma plc $722K
13,684 sh × $52.75
Exec May 20
Filed May 21 · 5:30 PM ET RPRXSALE Royalty Pharma plc $726K
13,684 sh × $53.06
Exec May 14
Filed May 15 · 5:30 PM ET RPRXSALE Royalty Pharma plc $822K
20,000 sh × $41.09
Exec Jan 30
Filed Feb 2 · 5:30 PM ET RPRXSALE Royalty Pharma plc $805K
20,000 sh × $40.26
Exec Jan 23
Filed Jan 26 · 5:30 PM ET RPRXSALE Royalty Pharma plc $790K
20,000 sh × $39.52
Exec Jan 16
Filed Jan 20 · 5:30 PM ET RPRXSALE Royalty Pharma plc $816K
20,000 sh × $40.78
Exec Jan 9
Filed Jan 13 · 5:30 PM ET